Dan Kracov is chair of Arnold & Porter’s Global Life Sciences Industry group, which was honored by Law360 in 2020 and 2022 as a “Life Sciences Practice Group of the Year.” For decades, he has been one of the foremost Food and Drug Administration lawyers in the country, and his expertise in critical regulatory matters has been widely recognized by Chambers, the Legal Times, Best Lawyers in America, and many other publications. Most recently, Dan received the Food and Drug Law Institute (FDLI) Distinguished Service and Leadership Award. A particular focus of his practice is assisting pharmaceutical, biotechnology, medical device, and diagnostic companies, including start-up companies, trade associations, and large manufacturers, negotiate challenges relating to the development, approval, and marketing of FDA-regulated products. In addition to day-to-day counseling on regulatory and compliance strategies and concerns, Dan regularly handles product and compliance-related government and internal investigations, the development of global corporate compliance programs, and due diligence in financings, mergers, and acquisitions. He also has a widely recognized experience in biomedical public policy matters, including Congressional investigations and advising on FDA-related legislation. He received his JD from the University of Virginia in 1988.